AstraZeneca PLC (AZN)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

15,288.00p

Buy

15,292.00p

arrow-up294.00p (+1.96%)

Prices updated at 02 Apr 2026, 19:03 BST
| Prices minimum 15 mins delay
|
Prices in GBX
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.
FTSE All-Share
arrow-up0.59%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Mr. Michel Roger Demare
CEO
Mr. Pascal Soriot
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
96,100
Head office
1 Francis Crick Avenue
Cambridge
United Kingdom
CB2 0AA
mobile
+44 2037495000
letter
ir@astrazeneca.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Philip A J Broadley
Non-Executive Director, Senior Independent Director
-
Mr. Michel Roger Demare
Non-Executive Director, Chairman
-
Ms. Sherilyn S. McCoy
Non-Executive Director
-
Mr. Marcus Wallenberg
Non-Executive Director
-
Ms. Diana Layfield
Non-Executive Director
-
Ms. Anna Olive Magdelene Manz
Non-Executive Director
-
Professor Nazneen Rahman
Non-Executive Director
-
Ms. Birgit M. Conix
Non-Executive Director
-
Professor Tony Mok
Non-Executive Director
-
Dr. Euan A. Ashley
Non-Executive Director
-
Ms. Karen Knudsen
Non-Executive Director
-
Dr. Aradhana Sarin
Executive Director, Chief Financial Officer
-
Mr. Pascal Soriot
Executive Director, Chief Executive Officer
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Blue Owl Credit Advisors LLC104,017,000
Blue Owl Credit Income Corp104,017,000
Capital Research and Management Company58,717,718
Capital Group39,590,761
BlackRock Fund Advisors30,036,313

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
05 Mar 2026Transfer in
04 Mar 2026Transfer in
04 Mar 2026Transfer in
18 Dec 2025Sale
17 Dec 2025Transfer in
17 Dec 2025Transfer out
12 Nov 2025Sale
07 Nov 2025Transfer out
07 Nov 2025Transfer in
09 Sep 2025D
14 Aug 2025Sale
10 Jun 2025Transfer out
21 May 2025Transfer in
30 Apr 2025Purchase
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.